1-9 of 9
Yingwan Luo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of Selinexor Sequential Azacytidine in Newly Diagnosed Patients with Myelodysplastic Syndromes EB1 or EB2: A Single-Center, Single-Arm, Phase Ib/II Trial

Liya Ma, Wenli Yang, Xinping Zhou, Li Ye, Gaixiang Xu, Chao Hu, Yingwan Luo, Chunmei Yang, Zheng Ge, Hongyan Tong
Journal: Blood
Blood (2023) 142 (Supplement 1): 1856.
https://doi.org/10.1182/blood-2023-183101
Published: 2023
Journal Articles

The M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway

Lingxu Jiang, Xinping Zhou, Chao Hu, Chen Mei, Gaixiang Xu, Liya Ma, Yanling Ren, Li Ye, Lu Wang, Yingwan Luo, Jie Jin, Jie Sun, Hongyan Tong
Journal: Blood
Blood (2022) 140 (Supplement 1): 6894–6895.
https://doi.org/10.1182/blood-2022-165203
Published: 2022
Journal Articles

EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes

Qi Zhang, Wei Lang, Lu Wang, Wenli Yang, Yingwan Luo, Shuanghong Zhu, Lingxu Jiang, Yuxia Wang, Chen Mei, Xinping Zhou, Yanling Ren, Liya Ma, Li Ye, Xingnong Ye, Gaixiang Xu, Jie Sun, Jie Jin, Hongyan Tong
Journal: Blood
Blood (2022) 140 (Supplement 1): 9767–9768.
https://doi.org/10.1182/blood-2022-165886
Published: 2022
Journal Articles

Co-Mutation Landscape and Clinical Significance of RAS Pathway Related Gene Mutations in Patients with Myelodysplastic Syndrome

Yanling Ren, Wei Lang, Chen Mei, Yingwan Luo, Jie Jin, Hongyan Tong
Journal: Blood
Blood (2022) 140 (Supplement 1): 12305.
https://doi.org/10.1182/blood-2022-169177
Published: 2022
Journal Articles

15-Days Duration of Venetoclax Combined with Azacitidine in the Treatment of Relapsed/Refractory High-Risk Myelodysplastic Syndromes: A Retrospective Single-Center Study

Hongyan Tong, Chen Mei, Yanling Ren, Xinping Zhou, Yingwan Luo, Jie Jin
Journal: Blood
Blood (2022) 140 (Supplement 1): 12351–12352.
https://doi.org/10.1182/blood-2022-168938
Published: 2022
Journal Articles

The Transcriptional Factor ONECUT3 Is a Driver and Therapeutic Target for Complex Karyotype MDS

Yingwan Luo, Xiaomin Feng, Wei Lang, Chen Mei, Rongzhen Xu, Gang Huang, Hongyan Tong
Journal: Blood
Blood (2022) 140 (Supplement 1): 4018–4019.
https://doi.org/10.1182/blood-2022-166618
Published: 2022
Journal Articles

Mutation Status and Burden Can Improve Prognostic Prediction of Patients with Lower-Risk Myelodysplastic Syndromes

Lingxu Jiang, Yingwan Luo, Jie Jin, MD PhD, Hongyan Tong
Journal: Blood
Blood (2019) 134 (Supplement_1): 3008.
https://doi.org/10.1182/blood-2019-125660
Published: 2019
Journal Articles

Targeting MiR-126 Blocks Progression of Myelodysplastic Syndrome and Transformation into Acute Myeloid Leukemia

Huafeng Wang, MD, Jie Sun, PhD, Dandan Zhao, MD, Hongyan Tong, Herman Wu, BS, Xia Li, PhD, Yingwan Luo, MD, Dan Dong, PhD, Tinisha McDonald, MS, Anthony Stein, MD, Monzr M. Al Malki, MD, Flavia Pichiorri, PhD, Nadia Carlesso, MD, Ya-Huei Kuo, PhD, Bin Zhang, PhD, Guido Marcucci, MD, Ling Li, PhD, Jie Jin, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1707.
https://doi.org/10.1182/blood-2019-130375
Published: 2019
Journal Articles

The High NRF2 Expression Confers Chemotherapy Resistance through Upregulated DUSP1 in Myelodysplastic Syndromes

Peipei Lin, Yanling Ren, Xinping Zhou, Chen Mei, Chao Hu, Yingwan Luo, Yile Zhou, Xiaomei Yan, Gang Huang, PhD, Hongyan Tong, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2956.
https://doi.org/10.1182/blood.V130.Suppl_1.2956.2956
Published: 2017